Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

NCT05031806 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: iNexin™ (0.08% aCT1)
DRUG: iNexin™ (0.4% aCT1)
DRUG: iNexin™ (2.0% aCT1)
DRUG: Vehicle (eye drop formulation without aCT1)

Sponsor

Xequel Bio, Inc.

Collaborators

[object Object]